EVALUATION OF USE antiemetic drugs BREAST CANCER PATIENTS UNDERGOING CHEMOTHERAPY WHICH HOSPITAL IN DR. Sardjito PERIOD IN 2012
ABSTRACT: Nausea and vomit caused by chemotherapy is one of side effect most often influence life quality of cancer patient undergoing chemotherapy. Objective of this research was to identity antiemetic provided to patient with breast cancer got chemotherapy and suitability of antiemetic drug used in Dr. Sardjito Hospital of Yogyakarta. This is non experimental descriptive research on patient with breast cancer visiting oncology clinic at Dr Sardjito hospital in 2012. Inclusion criteria are breast cancer inpatient obtaining chemotherapy and receive antiemetic therapy for nausea and vomit after chemotherapy. Analysis was done by evaluating suitability of antiemetic used in nausea and vomit management after chemotherapy using standard from National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) of 2010 including evaluations of indication suitability, drug suitability, dosage suitability and patient outcome after obtaining antiemetic therapy. The result indicated that there were 68 patients with 179 chemotherapy episodes obtained premedication antiemetic and 27 patients (52 chemotherapy episodes) experienced nausea and vomit after chemotherapy. Indication suitability in chemotherapy episode with nausea and vomit side effect is 100%. Drug suitability in premedication antiemetic and dosage suitability are 95% and 95.53%, respectively. Clinical outcome of patient receiving antiemetic indicated that 29.05% still experienced nausea and vomit effect and 70.95% patients did not experience nausea and vomit effect.
